baber/WOPTO huggingface dataset:
Patent NZ-539997-A (NZ)
Title: Process for the production of a cellulosic product such as paper or pulp
Inventor: TOKARZ MAREK
IPC: D21H21/10
Filed: 2003-11-07
Abstract: A process for the production of a cellulosic product is disclosed which comprises: (i) providing an aqueous suspension containing cellulosic fibres, and optional filler; (ii) adding to the suspension a clay having 3R2 stacking; and (iii) dewatering the obtained suspension. Also disclosed is a process for the production of a cellulosic product which comprises: (i) providing an aqueous suspension containing cellulosic fibres, and optional filler; (ii) adding to the suspension a cationic clay and then one or more drainage and retention aids comprising at least one cationic polymer; and (iii) dewatering the obtained suspension. Cellulosic products such as paper and pulp comprising clay having 3R2 stacking are also disclosed.
Patent NZ-541586-A (NZ)
Title: Fire retardant elevated floor structure for a building
Inventor: FRANKLIN ALAN GORDON
Filed: 2005-07-29
Abstract: A fire retardant elevated floor structure for a building comprises a number of parallel and spaced apart joists 12 supported by support means 13. At least one fire retardant panel 15 is also provided having at least two parallel and opposed edges 17. The parallel and opposed edges 17 are positioned parallel to, and located on top of, the respective joist 12.
Patent NZ-543633-A (NZ)
Title: Oral treatment devices that include a thin, flexible barrier layer and an endoskeleton treatment or adhesive composition
Inventor: ALLRED PETER M
IPC: A61C19/06
Filed: 2005-05-07
Abstract: Oral treatment devices (100) include a barrier layer (102) and an oral treatment composition (112), and optionally an auxiliary adhesive composition, that acts as an endoskeleton so as to at least partially contribute to maintaining the barrier layer (102) in the shape of a dental tray, or in a tray-like configuration, prior to use. The barrier layer (102) protects the oral treatment (112) and/or adhesive composition from saliva or moisture during use. The treatment and/or auxiliary adhesive compositions (112) can have a consistency ranging from a sticky, viscous gel or a solid. They preferably include a tissue adhesion agent comprising a hydrophilic polymer.
Patent NZ-545340-A (NZ)
Title: Casein hydrolyzate, process for producing the same and use thereof
Inventor: YAMAMOTO NAOYUKI
IPC: A23L1/305
Filed: 2004-07-30
Abstract: Provided is a casein hydrolysate comprising free amino acids and peptides obtained by hydrolyzing animal milk casein with enzymes of average amino acid chain length of not longer than 2.1 comprising peptidases capable of cleaving a peptide bond Pro-Xaa, leucine aminopeptidases and at least one of neutral protease I and neutral protease II, all of which are extracellular enzymes derived from Aspergillus oryzae, wherein said peptides comprise in vivo indigestible dipeptides with a sequence Xaa-Pro and tripeptides with a sequence Xaa-Pro-Pro at amounts of at least 5 and 1 wt%, respectively. of a total amount of the free amino acids and the peptides in the hydrolysate.
Patent NZ-546290-A (NZ)
Title: Fused pentalyclic polyethers
Inventor: BADEN DANIEL G
IPC: A61K31/42
Filed: 2004-09-20
Abstract: Disclosed is brevanal and derivatives of the formula shown wherein: R is C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkyl esters, C1-C12 alkyl amides, C4-C12 alkenyl esters, C1-C12 alkylaryl esters, C4-C12 alkenylaryl esters, C4-C12 alkenyl amides, C1-C12 alkoxy, formyI C1-C12alkyl, formyI C2-C12alkenyl, alkanoyI C1-C12 alkyl, alkanoyI C2-C12 alkenyl, carboxy C1-C12alkyl, carboxy C2-C12alkenyl, wherein the alkyl and alkenyl groups are optionally substituted with 1-6 substituent groups as defined; OR1 is OH or -O(CO)CH3 ; R2 is -CH=CHCH=CH2, -CH2-phenyl, or -CH2-pyridyl, wherein the phenyl and pyridyl groups are optionally substituted at each substitutable position as define; or pharmaceutically acceptable salts, solvates, esters, amides, hydrates, or combinations thereof. The compounds disclosed have action as a brevetoxin antagonist and additionally useful for treating conditions associated with decreased mucus clearance.
Patent NZ-551112-A (NZ)
Title: Adjustable rucksack harness
Inventor: HURN MARTYN
IPC: A45F3/04
Filed: 2005-05-10
Abstract: The invention relates to a rucksack harness comprising central adjustment means (6) located on an upper part of a rear wall of a rucksack and a central web (8) adjustably attached to the rear wall of the rucksack by the central adjustment means. The central web runs downwardly along the length of the rucksack to a branch point (4) at which the central web is bifurcated to form to a pair of side webs (10). The pair of side webs pass first through a pair of loops (12) positioned at either side of a lower part of the rear wall of the rucksack, and then pass upwardly along either side of the rucksack and under a stabilizing member (14) or spreader plate. The ends of the pair of side webs are attached to a pair of shoulder carrier straps (16), where the length of the shoulder carrier straps in relation to the rear of the rucksack may be adjusted by pulling the end of the central web through the central adjustment means.
Patent NZ-553957-A (NZ)
Title: Panel transporter with fold-up panel supports
Inventor: COUNSELL GEOFFREY ALAN
Filed: 2007-03-19
Abstract: A transporter (1) is disclosed. The transporter (1) includes an upper deck (2) for supporting articles and a plurality of individual pivotable supports (4) attached to the transporter (1). The supports are reversibly pivotable about respective pivot axes between a flat configuration extending substantially coplanar with, or below the deck (2), and a raised supporting configuration where the supports extend above the deck. At least one the supports include a bearing surface for inhibiting movement of the transported articles in at least one direction, in a plane substantially parallel with the respective pivot axis. This allows the transportation of flat construction components such as pre-cast concrete slabs in a substantially upright orientation with the plane of the construction components parallel with the major axis of the transporter (1).
Patent NZ-568189-A (NZ)
Title: Pharmaceutical formulations for sustained drug delivery
IPC: A61K38/095
Filed: 1997-12-11
Abstract: Disclosed is a method for preparing a pharmaceutical formulation, comprising: providing a pharmaceutically active peptidic compound and a carrier macromolecule, wherein the pharmaceutically active peptidic compound is not an LHRH analogue; combining the pharmaceutically active peptidic compound and the carrier macromolecule under conditions such that a water-insoluble complex of the pharmaceutically active peptidic compound and the carrier macromolecule is an ionic interaction, and wherein the pharmaceutically active peptidic compound in said complex is in excess relative to the carrier macromolecule on a weight basis; and preparing a pharmaceutical formulation comprising the water insoluble complex.
Patent NZ-570395-A (NZ)
Title: Methods and compositions for modifying plant biosynthetic pathways
Inventor: TIAN LI
IPC: A01H5/00
Filed: 2007-02-08
Abstract: Disclosed is a DNA construct comprising a promoter functional in a plant operably linked to a nucleic acid sequence encoding a fusion polypeptide comprising a first enzyme and a second enzyme, wherein the first enzyme is a membrane-bound enzyme and the second enzyme is a soluble enzyme, wherein a product of the first enzyme is a substrate of the second enzyme or wherein a product of the second enzyme is a substrate of the first enzyme, and wherein the fusion polypeptide comprises the enzymatic activity of the first and second enzymes, and wherein the first enzyme and second enzymes are isoflavone synthase and chalcone isomerase. The construct can be used to produce isoflavones in plants.
Patent NZ-574658-A (NZ)
Title: Combination of azelastine and steroids such as fluticasone and mometasone for nasal and ocular use
Inventor: LULLA AMAR
IPC: A61K31/573
Filed: 2003-06-13
Abstract: Disclosed is a pharmaceutical formulation which comprises: (1) azelastine, or a pharmaceutically acceptable salt thereof (such as azelastine hydrochloride); and (2) in an amount from 50 micrograms/ml to 5 mg/ml of the formulation, (a) fluticasone or a pharmaceutically acceptable ester thereof, provided that the pharmaceutically acceptable ester is not fluticasone propionate or fluticasone valerate, (b) mometasone or a pharmaceutically acceptable ester thereof, provided that the pharmaceutically acceptable ester is not mometasone furoate or mometasone furoate monohydrate, or (c) ciclesonide. The preferred formulations are in a form suitable for nasal or ocular administration. (62) Divided Out of 560480
Patent NZ-574704-A (NZ)
Title: System and method for wireless transactions
Inventor: MECHALEY ROBERT G
IPC: H04W84/00
Filed: 2007-08-16
Abstract: A system and a method for wireless point-of-sale transactions for use with frequencies licensed for wide-area networks are disclosed. The system comprises a retail facility open to consumers; a transmitter associated with the retail facility and located proximate the retail facility; a receiver associated with the retail facility and configured to receive data communications from a consumer wireless device; an antenna operatively coupled to the transmitter and the receiver; and a controller operatively coupled to the transmitter and the receiver. The transceiver is configured to have a limited transmission range on licensed frequencies and to transmit data communications to the consumer wireless device. The controller is configured to detect when the consumer wireless device is within range of the transmitter. Upon detection that the consumer wireless device is within range of the transmitter, the controller is configured to communicate with the consumer wireless device in a base station registration process between the consumer wireless device and the controller. The controller is also configured to receive identification data associated with the consumer wireless device that uniquely identifies the consumer wireless device and to use the received identification data to complete a transaction within the retail facility.
Patent NZ-575510-A (NZ)
Title: A lice comb with a wiper which sweeps captured lice into a receptacle
Inventor: MAOR MOSHE
IPC: A01K13/00
Filed: 2007-08-23
Abstract: A lice comb (10) is disclosed. The comb includes teeth (14), a receptacle (22), and a wiper. The teeth capture lice when they are passed through hair. The wiper moves across the surface of the teeth to wipe captured lice into the receptacle (22). The receptacle (22) has an adhesive inner surface that prevents the lice from escaping.
Patent NZ-578970-A (NZ)
Title: Antimicrobial peptides comprising one basic amino acid
Inventor: O'NEIL DEBORAH
IPC: A61K38/08
Filed: 2008-01-28
Abstract: Disclosed is use of a peptide, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or alleviation of a fungal infection wherein the peptide consists of a sequence of 9 to 15 amino acids wherein all the amino acids in said sequence are arginine subject to 0, 1 or 2 substitutions to the amino acid sequence.
Patent NZ-579081-A (NZ)
Title: A flat arrow shaped upwards pointing warning sign for a traffic cone for overhead hazards, connected coaxially to the cone by a concentric sleeve
Inventor: RICHARDSON BARRY NOEL
IPC: E01F9/669
Filed: 2010-08-17
Abstract: A portable sign (15) for a traffic cone (11) for directing the attention of a person seeing the sign to the presence of overhead danger or risk. The sign contains symbols or markings (16) to indicate the type of hazard above. The sign is arrow or triangular shaped with the apex pointing upwards with the tail forming the concentric base (17) or sleeve that fits over the top (13) of the traffic cone coaxially to securely retain and locate the warning sign. The sign is constructed from a single sheet of material, folded and the opposing sides fastened or taped together, or made from two individual blanks or pieces fixed together to form the sign. The sign can be stored flat when not in use.
Patent NZ-579361-A (NZ)
Title: Heterocyclic cyclopamine analogs and methods of use thereof
Inventor: CASTRO ALFREDO C
IPC: A61K31/4747
Filed: 2008-03-07
Abstract: Disclosed are heterocyclic cyclopamine compounds represented by general formulae 1a and 1b. The compounds are used for the treatment of cancer.
Patent NZ-588807-A (NZ)
Title: Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
Inventor: PERNERSTORFER JOSEF
IPC: C07C235/54
Filed: 2009-04-22
Abstract: Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification, and processes for its preparation. The compounds are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, are useful in the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure.
Patent NZ-590423-A (NZ)
Title: Using a float to isolate the vertical and horizontal forces on a mooring line from an anchor to a floating platform
Inventor: HENRIKSEN SVEIN DAG
IPC: B63B21/50
Filed: 2009-06-24
Abstract: 590423 Disclosed is a system for mooring a floating plant for the production of energy from current in a body of water. The system comprises a ballastable plant (10). The ballastable plant (10) comprises at least one generator (7) for energy production and at least one elongate first mooring element (24). The first mooring element (24) at a first end is connected to one end of the plant (10) and the second end of the first mooring element (24) is connected to a buoyant element (50). The buoyant element (50) is anchored (29) to the bottom of the body of water via at least one second elongate mooring element (6). The second end of the first mooring element (24) is connected to the buoyant element (50) via an adjustable first suspension means (9). The second elongate mooring element (6) is connected to the buoyant element via at least one adjustable suspension means (8). The second end of the first mooring element (24) is connected to the second elongate mooring element (6) via an elongate intermediate portion (6a) between the first (9) and second (8) suspension means. The first mooring element (24) runs almost horizontally to the body of water.
Patent NZ-597413-A (NZ)
Title: Packaging material with integrated pressure relief valve charaterised by its stretch properties under a standard test
Inventor: LYKKE KIRSTEN
IPC: B32B3/08
Filed: 2010-07-02
Abstract: A packaging material for forming at least a part of a package for a product releasing gasses comprises a one-way pressure relief valve (18) including a first inner film (10), being provided with at least one inlet opening (13,14) therethrough, and a second outer film (11) covering the at least one inlet opening (13, 14) and being bonded to the first inner film (10) to form a channel portion (12) between the inner and the outer film. The channel portion (12) communicates with the surroundings of the package through at least one outlet opening (15) spaced apart from the at least one inlet opening (13, 14). The pressure relief valve (18) further comprises a liquid (19) provided in the channel portion (12) and solid spacer means (17) provided in the channel portion (12) proximate to the at least one inlet opening (13, 14).The outer film (11) is a soft film having such a flexibility or elasticity that in a tensile test a force of less than 5 N is needed for elongating a test piece thereof having a width of 15mm by 5%.
Patent NZ-598510-A (NZ)
Title: Air purifying respirator having inhalation and exhalation ducts to reduce rate of pathogen transmission, with angled inlet and outlet airflow, with rotatable cover to vary direction of inhalation
Inventor: MORGAN III JUDGE WOODROW
IPC: A62B18/02
Filed: 2010-07-30
Abstract: A filter mask includes an oronasal cup, an inhalation directional cover, and an exhalation diverter body. The oronasal cup encloses a nose and mouth of a user. The oronasal cup is fluidly coupled with a filter. The inhalation directional cover is configured to be joined to the filter. The inhalation directional cover includes an elongated wing portion that is oriented in an inhalation direction that is angled with respect to the center axis of the filter. The exhalation diverter body is fluidly coupled with the oronasal cup. The exhalation diverter body defines an exhalation duct that directs exhaled air out of the oronasal cup along an exhalation direction. The inhalation direction and the exhalation direction are oriented away from a plane of interaction between the user and another person.
Patent NZ-598860-A (NZ)
Title: Flexibly usable box
Inventor: ORGELDINGER WOLFGANG
IPC: B65D6/18
Filed: 2009-11-06
Abstract: A flexibly usable box (10) includes a floor (12) and four side walls (14a, 14b, 14c, 14d) opposite to each other in pairs which extend from the floor (12) upwards in a vertical direction (16). One of the four side walls (14a-14d) is configured as an opening wall (14d) which in a closed state completely covers a side surface area and is movable into an opened state in which the opening wall (14d) only covers a part of the side surface area such that the opening wall (14d) in the opened state at least partially covers one of the adjacent side walls (14a, 14c) or the floor (12) of the box.
Patent NZ-600603-A (NZ)
Title: Bicyclic thiazoles as allosteric modulators of mglur5 receptors
Inventor: MACDONALD GREGOR JAMES
IPC: A61K31/428
Filed: 2010-12-16
Abstract: 600603 Disclosed herein is a compound of formula (I), wherein the variables are defined in the specification, and the use thereof in the treatment of neurological or psychiatric disorders. Addtionally disclosed is a product compising said compound and a mGluR5 orthosteric agonist for use in the treatment of neurological or psychiatric disorders. Specific embodiments of the compound include: 5,6-dihydro-2-(phenylethynyl)-7(4H)-benzothiazolone, 2-[(5-fluoro-3-pyridinyl)ethynyl]-5,6-dihydro-7(4H)-benzothiazolone, 2-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5,6-dihydro-1,3-benzothiazol-7(4H)-one, and 6,7-dihydro-5-(2-methoxyethyl)-2-(phenylethynyl)-thiazolo[5,4-c]pyridin-4(5H)one.
Patent NZ-601812-A (NZ)
Title: Implant cannula having an implant and method for securing implants in an injection cannula
Inventor: SPILGIES HEIKO
IPC: A61L31/00
Filed: 2011-02-17
Abstract: 601812 The disclosure relates to an injection cannula having an implant detachably secured in the cannula. The invention further relates to a method for detachably securing an implant in an injection cannula.
Patent NZ-602130-A (NZ)
Title: Solid composition for the oral administration of dyes and diagnostic use thereof
Inventor: MORO LUIGI
IPC: A61K49/00
Filed: 2011-03-02
Abstract: Disclosed herein is a method of endoscopic diagnostic evaluation of pathologies of the gastrointestinal tract in a subject, said method comprises administering to the subject a diagnostically effective amount of at least one solid composition of claim 1 within a 24 hour period preceding the endoscopic diagnostic evaluation and endoscopic diagnostically evaluating the gastrointestinal tract for said pathologies, wherein said solid composition is for oral administration and comprises: (a) at least one dye selected from among methylene blue, congo red, carmine indigo, toluidine blue or mixtures thereof; (b) a first matrix in which said at least one dye is incorporated, wherein said first matrix comprises: (i) at least one lipophilic compound selected from among saturated, unsaturated or hydrogenated long chain alcohols, saturated or unsaturated or hydrogenated fatty acids, salts thereof, esters or amides, mono-, di- or triglycerides of fatty acids, polyethoxylated derivatives thereof, waxes, ceramides, cholesterol, cholesterol derivatives or mixtures thereof having a melting point below 90°C and (ii) at least one amphiphilic compound selected from among polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidylethanolamine or a mixture thereof), ceramides, glycol alkyl ethers (such as for example, diethylene glycol monomethyI ether), alkyl sulfate or sulfosuccinate salts or mixtures thereof; (c) a second matrix comprising at least one hydrophilic compound selected from among polymers or copolymers of the acrylic or methacrylic acid, alkyl vinylpolymers, alkyl celluloses, hydroxyalkyl celluloses, carboxyalkyl cellulose, modified or plurisubstituted celluloses, polysaccharides, dextrins, pectins, starches, complex starches and starch derivatives, alginic acid, synthetic rubber, natural rubber, polyalcohols or mixtures thereof, wherein the first matrix is dispersed in the second matrix; (d) optionally other physiologically acceptable excipients; and (e) optionally a gastro-resistant coating selected from among polymers of the acrylic or methacrylic acid, copolymers of the acrylic or methacrylic acid, cellulose derivatives (such as for example cellulose acetate phthalate) hydroxybutyrate-based polymers, shellac or mixtures thereof.
Patent NZ-612214-A (NZ)
Title: Nutritional products including monoglycerides and fatty acids
Inventor: LASEKAN JOHN B
IPC: A23L33/00
Filed: 2011-12-21
Abstract: Disclosed is a nutritional product comprising a fat system, wherein the fat system comprises at least 10 wt% of a mixture of an unsaturated free fatty acid component and fatty acid-containing monoglycerides, and wherein the nutritional product is selected from a liquid emulsion or a powder reconstitutable into a liquid emulsion.
Patent NZ-612336-A (NZ)
Title: Novel substituted isoquinoline derivative
Inventor: HIDAKA HIROYOSHI
IPC: C07D417/12
Filed: 2011-12-21
Abstract: 612336 Disclosed are N-{ amino-alkyl} -isoquinoline-6-sulfonamide derivatives as represented by the general formula (I), a salt thereof, or a solvate of the derivative or the salt, wherein R3 and R4 each independently represent a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dialkylaminoalkyl group, or an aminoalkanoyl group; R5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, or an optionally substituted alkanoyl group, or R4 and R5 may form a saturated heterocyclic ring together with the adjacent nitrogen atom; A represents a linear or branched alkylene group having 2 to 6 carbon atoms and optionally having at least one substituent selected from a carboxyl group, a halogen atom, a cyano group, an oxo group, an alkenyl group, an alkynyl group, an alkoxy group, a hydroxyl group, an alkyloxycarbonyl group, an aminoalkyl group, an aryl group, a heteroaryl group, an optionally substituted aralkyl group, and an optionally substituted heteroarylalkyl group. Representative compounds include (R)-N-{ 1-(benzylamino)propan-2-yl} isoquinoline-6-sulfonamide dihydrochloride, (R)-N-{ 1-(ethylamino)propan-2-l} isoquinoline-6-sulfonamide dihydrochloride, (S)-N-{ 1-(butylamino)propan-2-yl} isoquinoline-6-sulfonamide dihydrochloride, (R)-N-{ 1-(isobutylamino)propan-2-yl} isoquinoline-6-sulfonamide dihydrochloride, (R)-N-{ 1-(2-fluorophenethylamino)propan-2-yl} isoquinoline-6-sulfonamide dihydrochloride, (R)-N-[1-{ 2-(1H-1,2,4-triazol-1-yl)ethylamino} propan-2-yl]isoquinoline-6-sulfonamide hydrochloride, (R)-1-amino-N-{ 1-(phenethylamino)propan-2-yl} isoquinoline-6-sulfonamide hydrochloride, (R)-N-{ 1-(phenethylamino)propan-2-yl} -1-hydroxyisoquinoline-6-sulfonamide hydrochloride and (R)-N-{ 1-(phenethylamino)propan-2-yl} -4-(thiophen-3-yl)isoquinoline-6-sulfonamide dihydrochloride. Further disclosed is a pharmaceutical composition containing a compound as defined above, for the prevention or treatment of glaucoma, ocular hypertension or cardiovascular disease (particularly hypertension).